Sp263
PANEL DISCUSSION
Date
May 18, 2024
Tracks
Related Products
THE SYMPTOM EXPERIENCE OF PERSONS WITH CROHNS DISEASE WITH ACTIVE DISEASE COMPARED TO THOSE WITH INACTIVE DISEASE-THE MAGIC IN IMAGINE STUDY
BACKGROUND: The Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects (IMAGINE) Strategy for Patient Oriented Research (SPOR) Chronic Disease Network is conducting a five-year multicenter prospective observational cohort study, Mind And Gut Interactions Cohort (…
MACROPHAGE LRRK2 HYPERACTIVITY IMPAIRS AUTOPHAGY AND INDUCES PANETH CELL DYSFUNCTION AND INTESTINAL INFLAMMATION
Background: _LRRK2_ variants (G2019S/N2081D) that increase Parkinson’s disease (PD) and Crohn’s Disease (CD) susceptibility are associated with LRRK2 kinase hyperactivity and suppress autophagy, suggesting that LRRK2 kinase inhibition, a strategy being explored for PD treatment, may also benefit CD…
DEVELOPMENT AND VALIDATION OF AN INTEGRATED RISK SCORE FOR PREDICTING FUTURE RISK OF CROHN'S DISEASE UP TO 7 YEARS BEFORE DIAGNOSIS IN HEALTHY FIRST-DEGREE RELATIVES: THE CCC-GEM PROJECT, A MULTICENTRE PROSPECTIVE COHORT STUDY
Although the cause of Crohn’s disease (CD) is unknown, recent studies have identified a number of biomarkers associated with the risk of developing CD in healthy at-risk individuals…
CHARACTERIZING EPITOPES AND ISOTYPES OF CROHN'S DISEASE-ASSOCIATED ANTI-GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR ANTIBODIES.
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) maintains mononuclear phagocytes (MNP) and supports intestinal immune homeostasis. Anti-GM-CSF autoantibodies (aGMAbs) are found in approx. 25% of all Crohn’s disease (CD) patients…
